Rockwell Medical to release Q2FY26 results on August 13, 2026

0 min read Updated on 16 Jul 2026, 04:26 PM

Reviewed by

Suketu GScanX News Team

AI Summary

Rockwell Medical, Inc. will announce its Q2FY26 financial and operational results on August 13, 2026, via a press release and subsequent webcast. The event will feature leadership discussing the quarter's performance, highlighting the company's role in the hemodialysis market.

*this image is generated using AI for illustrative purposes only.

Rockwell Medical, Inc. will release its financial and operational results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026. The company develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The announcement will provide insights into its performance during the quarter.

The company will issue a press release at 6:00 a.m. ET, followed by a live webcast at 8:00 a.m. ET. The webcast will include a discussion of the second quarter 2026 financial and operational results, followed by a question-and-answer session.

Webcast Details

Detail	Information
Date	Thursday, August 13, 2026
Time	8:00 a.m. ET
Webcast and Replay	www.RockwellMed.com/Results
Format	Discussion of Q2FY26 results followed by Q&A

Speakers

The webcast will feature:

Mark Strobeck, Ph.D. — President and Chief Executive Officer
Jesse Neri — SVP, Chief Financial Officer

Rockwell Medical focuses on innovative growth strategies to enhance its products and processes, aiming to deliver value to the healthcare system. The company's products are vital for patients with end-stage kidney disease.

What market trends in the dialysis sector might influence Rockwell Medical's Q2 2026 performance?

How will the company's innovative growth strategies impact its competitive position in the hemodialysis market?

What are the potential financial implications of new product developments or expansions announced during the webcast?

Read Next Article

HC Wainwright raises Rockwell Medical price target to $20

0 min read Updated on 09 Jul 2026, 04:01 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

AI Summary

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Rockwell Medical and raises the price target from $2 to $20, indicating strong confidence in the company's future performance.

*this image is generated using AI for illustrative purposes only.

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Rockwell Medical, citing a strong outlook for the company. The firm significantly raised the price target for the stock, moving it from $2 to $20. This adjustment reflects an increased confidence in the company's future performance and market position.

The revised price target of $20 represents a substantial increase over the previous target of $2. This change underscores the analyst's bullish stance on Rockwell Medical's potential. The company, listed on NASDAQ under the ticker RMTI, continues to be viewed favorably by the firm.

The decision to maintain the Buy rating alongside the higher price target suggests that Rockwell Medical is expected to deliver significant value to shareholders. The specific drivers behind this revised valuation were not detailed in the analyst note.

What specific catalysts or milestones does HC Wainwright anticipate will drive Rockwell Medical's growth to justify the $20 price target?

How might this significant price target increase influence investor sentiment and trading volume for RMTI in the short term?

What are the potential risks or challenges that could prevent Rockwell Medical from achieving this revised valuation?